Bristol Myers Squibb (BMY) Income from Continuing Operations (2009 - 2026)

Bristol Myers Squibb has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 2679000000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 8.81% year-over-year to 2679000000.0; the TTM figure through Mar 2026 stood at 7273000000.0 (up 33.77% YoY), while the FY2025 annual figure was 7056000000.0, up 178.99% from the prior year.
• Income from Continuing Operations advanced to 2679000000.0 in Q1 2026, from 1086000000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for BMY reached as high as 2679000000.0 in Q1 2026 and fell as low as 11908000000.0 in Q1 2024.
• The 5-year median for Income from Continuing Operations is 1684000000.0 (2024), against an average of 893352941.18.
• Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 625.28% — and 2025, when it soared 1328.95%.
• A 5-year view of Income from Continuing Operations shows it stood at 2025000000.0 in 2022, then dropped by 12.99% to 1762000000.0 in 2023, then tumbled by 95.69% to 76000000.0 in 2024, then soared by 1328.95% to 1086000000.0 in 2025, then soared by 146.69% to 2679000000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 2679000000.0, 1086000000.0, and 2195000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.